| 李波 肖凤仪 伍立群 方恋 周婷.奈达铂联合紫杉醇注射液对卵巢癌手术患者ROMA指数和HE4水平的影响[J].,2016,16(29):5752-5755 |
| 奈达铂联合紫杉醇注射液对卵巢癌手术患者ROMA指数和HE4水平的影响 |
| Effect of Oxaliplatin Combined with Paclitaxel Injection on ROMA andSerumLevel of HE4 in Patients with Ovarian Cancer |
| |
| DOI： |
| 中文关键词: 奥沙利铂 紫杉醇注射液 卵巢癌 ROMA 指数 HE4 |
| 英文关键词: Oxaliplatin Paclitaxel injection Ovarian cancer ROMA index HE4 |
| 基金项目:湖北省自然科学基金项目(2009CDA060) |
|
| 摘要点击次数: 729 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：探讨奈达铂联合紫杉醇注射液对卵巢癌术后患者ROMA 指数、HE4 水平的影响及临床疗效。方法：选取我院收治的
卵巢癌术后患者70 例，随机分为实验组和对照组，每组35 例。对照组采用紫杉醇注射液治疗；实验组在对照组基础上联合奈达
铂注射液治疗。观察并比较治疗前后两组患者ROMA 指数、血清CA125 和HE4 水平、生存期、临床疗效及不良反应情况。结果：
与治疗前相比，治疗后两组患者ROMA 指数、血清CA125 及HE4 水平均下降，差异具有统计学意义(P＜0.05)；与对照组比较，实
验组患者治疗后ROMA 指数、血清HE4 及CA125 水平较低，差异具有统计学意义(P＜0.05)；与对照组比较，实验组患者生存期
明显延长，差异具有统计学意义(P＜0.05)。结论：奈达铂联合紫杉醇注射液治疗卵巢癌具有显著的临床疗效，能够降低ROMA 指
数和血清CA125、HE4水平，而且毒副作用较小，可在临床进一步推广应用。 |
| 英文摘要: |
| Objective:To investigate the effect of oxaliplatin combined with paclitaxel injection on the ROMA index, and the
serum levels of HE4 in patients with ovarian cancer.Methods:70 patients with ovarian cancer who were treated in our hospital were selected
and randomly divided into the experiment group and the control group, with 35 cases in each group. The patients in the control
group were treated with paclitaxel injection, while the patients in the experiment group were treated with oxaliplatin combined with paclitaxel
injection. Then the ROMA index, the serum levels of CA125 and HE4, the clinical curative effect and adverse reactions in the
two groups were observed and compared before and after the treatment.Results:Compared with before treatment, the ROMA index and
the serum levels of CA125 and HE4 decreased in the two groups after the treatment, and the differences were statistically significant
(P<0.05); Compared with control group after the treatment, the ROMA index and the serum levels of CA125 and HE4 in the experiment
group were lower, and the differences were statistically significant (P<0.05); Compared with the control group, the length of survival in
the experiment group was longer, and the difference was statistically significant (P<0.05).Conclusion:Oxaliplatin combine with paclitaxel
injection has better clinical efficacy on the treatment of ovarian cancer, which can reduce the serum levels of CA125 and HE4 and ROMA
index with lower adverse reactions, and it is worthy of clinical application. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
